Immune checkpoint blockade opens a new way to cancer immunotherapy
Sanam Sadreddini1, Behzad Baradaran1, Ali Aghebati-Maleki1,2
1Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Among the main promising systems to triggering therapeutic antitumor immunity is the blockade of immune checkpoints. Immune checkpoint pathways regulate the control and eradication of infections, malignancies, and resistance against a host of autoantigens. Initiation point of the immune response is T cells, which have a critical role in this pathway. As several immune checkpoints are initiated by ligand-receptor interactions, they can be freely blocked by antibodies or modulated by recombinant forms of ligands or receptors. Antibodies against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) were the first immunotherapeutics that achieved the US Food and Drug Administration approval. Preliminary clinical results with the blockers of additional immune checkpoint proteins, such as programmed cell death protein 1 (PD-1) indicate extensive and different chances to boost antitumor immunity with the objective of conferring permanent clinical effects. This study provides an overview of the immune checkpoint pathways, including CTLA-4, PD-1, lymphocyte activation gene 3, T-cell immunoglobulin and mucin domain 3, B7-H3, and diacylglycerol kinase α and implications of their inhibition in the cancer therapy.
Insights
Blocking immune checkpoints like CTLA-4 and PD-1 shows promise for cancer therapy by enhancing antitumor immunity. This approach offers new avenues for durable clinical effects in cancer treatment.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Immune checkpoints are critical regulators of T cell responses, controlling autoimmunity and tumor immunity.
- Dysregulation of immune checkpoints can lead to uncontrolled infections, malignancies, and autoimmune diseases.
- Targeting immune checkpoints offers a promising strategy for cancer immunotherapy.
Purpose of the Study:
- To provide a comprehensive overview of key immune checkpoint pathways.
- To discuss the therapeutic implications of inhibiting these pathways in cancer treatment.
- To highlight the potential of immune checkpoint blockade for achieving durable antitumor responses.
Main Methods:
- Review of current literature on immune checkpoint pathways.
- Analysis of clinical data regarding immune checkpoint inhibitors.
- Discussion of various immune checkpoint targets including CTLA-4, PD-1, LAG-3, TIM-3, B7-H3, and DGKα.
Main Results:
- Antibodies targeting CTLA-4 were the first FDA-approved immunotherapeutics.
- Inhibitors of PD-1 demonstrate significant potential in boosting antitumor immunity.
- Several other immune checkpoints are being investigated for their therapeutic efficacy.
Conclusions:
- Immune checkpoint blockade represents a powerful strategy for cancer therapy.
- Targeting multiple immune checkpoints may enhance therapeutic outcomes.
- Further research into immune checkpoint pathways could lead to more effective cancer treatments.
Related Concept Videos
01:29Neuromuscular Junction And Blockade
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
01:27Tumor Immunotherapy
01:38What is the Immune System?
01:36Humoral Immune Responses
01:31Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...